Our Portfolio

export-table

Export table

FILTERS

Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options

PRODUCT NAME

THERAPEUTIC AREA

PHARMACEUTICAL
FORM

STRENGTH

REFERENCE
PRODUCT

DOSSIER
AVAILABILITY

Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
5/850 mg
5/1000 mg
Xigduo / Astra Zeneca
2022
Alimentary tract & metabolism
Film-coated tablets
10 mg
25 mg
Jardiance / Boehringer Ingelheim
2021
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
2022
Cardiovascular System
Tablets
5 mg
10 mg
Nebilet / Menarini
2022
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
2023
Respiratory system
Inhalation powder
44 mcg
Seebri Breezhaler / Novartis
2023
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
2023
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
2022
Antineoplastic & Immunomodulating Agents
Film-coated tablets
5 mg
10 mg
Xeljanz / Pfizer
Early stage
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Early stage
Nervous system
Film-coated tablets
5 mg
10 mg
15 mg
20 mg
Brintellix / H. Lundbeck A/S
2023
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned

DISCLAIMER
The above list is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

Our Portfolio

Empagliflozin* / Linagliptin* NEW!

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Glyxambi/ Boehringer Ingelheim

STRENGTH

10 mg/5 mg
 | 25 mg/5 mg

DOSSIER AVAILABILITY

2024

Dapagliflozin* / Metformin (1)

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Xigduo / Astra Zeneca

STRENGTH

5/850 mg
 | 5/1000 mg

DOSSIER AVAILABILITY

2022

Empagliflozin* (1)

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Jardiance / Boehringer Ingelheim

STRENGTH

10 mg
 | 25 mg

DOSSIER AVAILABILITY

2021

Empagliflozin* / Metformin

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Synjardy / Boehringer Ingelheim

STRENGTH

5mg/500mg
 |  5mg/850mg
 | 5mg/1000 mg
 | 12.5mg/500mg
 | 12.5mg/850mg
 | 12.5mg/1000mg

DOSSIER AVAILABILITY

2024

Linagliptin* / Metformin (2)

THERAPEUTIC AREA

Alimentary tract & metabolism

PHARMACEUTICAL FORM

Film-coated tablets

REFERENCE PRODUCT

Jentadueto / Boehringer Ingelheim

STRENGTH

2.5/500 mg
 | 2.5/850 mg
 | 2.5/1000 mg

DOSSIER AVAILABILITY

2022

Nebivolol

THERAPEUTIC AREA

Cardiovascular System

PHARMACEUTICAL FORM

Tablets

REFERENCE PRODUCT

Nebilet / Menarini

STRENGTH

5 mg
 | 10 mg

DOSSIER AVAILABILITY

2022

* Polpharma Group API

(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned